<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03990077</url>
  </required_header>
  <id_info>
    <org_study_id>HL-085-103</org_study_id>
    <nct_id>NCT03990077</nct_id>
  </id_info>
  <brief_title>Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC</brief_title>
  <official_title>A Phase I , Single Arm, Dose Escalation Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Kechow Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Kechow Pharma, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, open label, dose escalation study to evaluate tolerability, safety ,
      pharmacokinetics and efficacy in patients with KRAS mutant NSCLC by using HL-085 and
      Docetaxel.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>If no Dose-limiting toxicity (DLT) occurs in the first three subjects in Cycle 1, the dose will be escalated to the next dose level; If a DLT occurs in one of the first three subjects, three additional subjects will be enrolled for the same dose cohort, and undergo the same procedures. Dose -escalation is performed based on the scheduled dose groups until DLT occurs in two or more subjects in a dose group which consists of 3 or 6 subjects.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events (AEs)</measure>
    <time_frame>Duration of the study, estimated to be approximately 24 months</time_frame>
    <description>Number of Treatment-Related Adverse Events as Assessed by CTCAE v4.03 will be counted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>DLTs within the first cycle of therapy (up to 35 days)</time_frame>
    <description>The dose level immediately below the dose level at which more than 2 patients from a cohort of 3 to 6 patients experience a dose-limiting toxicity (DLT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Duration of the study, estimated to be approximately 24 months</time_frame>
    <description>ORR is the proportion of patients with a best overall response of complete response (CR) or partial response (PR), as assessed per response evaluation criteria in solid tumors (RECIST) v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Duration of the study, estimated to be approximately 24 months</time_frame>
    <description>Cmax is the maximum plasma concentration of HL-085 or metabolite(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration verus time curve(AUC)</measure>
    <time_frame>Duration of the study, estimated to be approximately 24 months</time_frame>
    <description>AUC of HL-085 or metabolites(s) after repeated dosing</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Nsclc</condition>
  <arm_group>
    <arm_group_label>dose escalation of HL-085 plus Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HL-085 will be administered as BID with specified dose. And Docetaxel will be taken as the instruction in the label ( 75mg/m2，IV).
f no Dose-limiting toxicity (DLT) occurs in the first three subjects in Cycle 1, the dose will be escalated to the next dose level; If a DLT occurs in one of the first three subjects, three additional subjects will be enrolled for the same dose cohort, and undergo the same procedures. Dose -escalation is performed based on the scheduled dose groups until DLT occurs in two or more subjects in a dose group which consists of 3 or 6 subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HL-085</intervention_name>
    <description>HL-085 ( Capsule) is one MEK inhibitor.</description>
    <arm_group_label>dose escalation of HL-085 plus Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel is an antineoplastic drug by inhibiting microtubule depolymerization, and attenuating of the effects of bcl-2 and bcl-xL gene expression.</description>
    <arm_group_label>dose escalation of HL-085 plus Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. KRAS mutation NSCLC.

          2. One measurable lesion as defined by RECIST 1.1 criteria for solid tumors.

          3. Chemotherapy, immunotherapy or radiotherapy ≥ 4 weeks prior to starting the study
             treatment.

          4. Surgery (except for tumor biopsy) or severe trauma ≤ 14 days prior to starting the
             study treatment.

          5. ECOG performance status of 0-1.

          6. Life expectancy ≥ 3 months.

          7. Ability to take the medicine orally.

          8. Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          1. Hypersensitivity to study drug ingredients or their analogues.

          2. Prior therapy with MEK-inhibitor.

          3. Receiving any other anti-cancer therapy at the same time .

          4. Active central nervous system (CNS) lesion.

          5. Bleeding symptoms at Grade 3 within 4 weeks prior to starting study treatment.

          6. ECG QTcB≥480msec in screening, or history of congenital long QT syndrome；

          7. Uncontrolled concomitant diseases or infectious diseases.

          8. Retinal diseases (Retinal Vein Occlusion (RVO) or Retinal pigment epithelial
             detachment (RPED) , et al.).

          9. History of HIV,HCV,HBV infection.

         10. Interstitial lung disease or interstitial pneumonitis, including clinically
             significant radiation pneumonitis will be excluded.

         11. Serum HCG test is positive.

         12. Other conditions that increase the risk of study and influence the result.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>YI LIU, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Kechow Pharma.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>YI LIU, MD, PhD</last_name>
    <phone>0086 21 51323990</phone>
    <email>liuy@kechowpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Science</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yuankai Shi</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 12, 2019</study_first_submitted>
  <study_first_submitted_qc>June 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2019</study_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

